biostudies-literatureScott IUNEI NIH HHS1066-1072https://www.ebi.ac.uk/biostudies/studies/S-EPMC10524366biostudies-literatureUnknown130(10)<h4>Purpose</h4>To investigate whether a nonlinear association between central subfield thickness (CST) on spectral-domain OCT and concurrent visual acuity letter score (VALS) exists in eyes treated initially with aflibercept or bevacizumab for macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).<h4>Design</h4>Long-term follow-up after a randomized clinical trial from 64 centers in the United States.<h4>Participants</h4>Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol.<h4>Methods</h4>Two-segment linear regression models were compared with simple linear regression models of VALS on OphthalmologySCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.PMC10524366U10 EY023521U10 EY023533U10 EY023529UG1 EY023533Scott IUOden NLVanVeldhuisen PCIp MSBlodi BASCORE2 Investigator GroupfalseSCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.<h4>Purpose</h4>To investigate whether a nonlinear association between central subfield thickness (CST) on spectral-domain OCT and concurrent visual acuity letter score (VALS) exists in eyes treated initially with aflibercept or bevacizumab for macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).<h4>Design</h4>Long-term follow-up after a randomized clinical trial from 64 centers in the United States.<h4>Participants</h4>Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol.<h4>Methods</h4>Two-segment linear regression models were compared with simple linear regression models of VALS on 2023-01-01T00:00:00Z2023 Oct2026-06-02T11:45:38.563Z2025-04-04T12:53:47.067ZS-EPMC105243663722081510.1016/j.ophtha.2023.05.023